Related references
Note: Only part of the references are listed.First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Morie A. Gertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Systemic amyloidosis
Ashutosh D. Wechalekar et al.
LANCET (2016)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis
Luisa Diomede et al.
BLOOD (2014)
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients
G. Palladini et al.
LEUKEMIA (2014)
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis
C. P. Venner et al.
LEUKEMIA (2014)
Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
Shikha Mishra et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2013)
Cdc42 regulates neutrophil migration via crosstalk between WASp, CD11b, and microtubules
Sachin Kumar et al.
BLOOD (2012)
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
Jennifer Ellis Ward et al.
BLOOD (2011)
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway
Jianru Shi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
